The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

GE Healthcare and Eisai Inc. to Partner on Alzheimer's Disease Research

<p class='bwalignc'> <i>Eisai Initiates Phase I Trial of BACE Inhibitor Utilizing GE's [</i><sup><i>18</i></sup><i>F]Flutemetamol</i> </p>

Wednesday, April 24, 2013

GE Healthcare and Eisai Inc. to Partner on Alzheimer's Disease Research

08:30 EDT Wednesday, April 24, 2013

CHALFONT ST. GILES, England (Business Wire) -- GE Healthcare today announced a research collaboration agreement with Eisai Inc. for use of the GE Healthcare investigational PET amyloid imaging agent, [18F]flutemetamol, to help select patients for a phase I clinical trial being conducted by Eisai. The trial evaluates Eisai's investigational compound E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor for the potential treatment of Alzheimer's disease (AD). The accumulation of beta amyloid in the brain is believed to play a role in the degeneration of neurons and is one of several pathological characteristics implicated in the development of AD.

“Alzheimer's disease is an important area of research for the industry and specifically for GE Healthcare,” said Pascale Witz, President and CEO of GE Healthcare, Medical Diagnostics. “This partnership may ultimately support the market entry of important therapies, and potentially, expedited time to market because the right patients have been identified for participation in clinical trials. Under terms of the agreement, GE Healthcare's proprietary software technology will be used during the trial to help support imaging data analysis.”

"Eisai has a long-standing commitment to Alzheimer's disease," said Lynn Kramer, MD, Chief Clinical Officer and President of the Neuroscience and General Medicine Product Creation Unit at Eisai Product Creation Systems. "Imaging plays a key role in our efforts to better understand the progression of the disease and identify potential patients for our clinical trials. Through this collaboration, Eisai hopes to bring important new treatment options to patients and caregivers who are affected by this devastating disease."

GE Healthcare takes a comprehensive approach to understanding a variety of neurological disorders such as Alzheimer's disease, Parkinson's disease, post-traumatic stress disorder, concussion, traumatic brain injury and Multiple Sclerosis through its ongoing research to uncover the causes, risks, and physical effects of these conditions. By collaborating with the pharmaceutical industry to assist in their development of the next generation of therapies to treat these disorders and working with potential partners in the industry, GE Healthcare can provide imaging support for clinical trials of therapeutic agents.

For more information about Eisai's Phase I trial, which is currently recruiting participants, please visit


GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

For our latest news, please visit

GE Healthcare
Aleisia Gibson
609 514 6046 (office)
201 289 3832 (mobile)

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail App

    The New Globe and Mail App for iPhone®, iPad® and Apple Watch download

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Secure Service
Customer Service
Advertising Privacy
Globe Recognition
Mobile Apps
Other Sections